J&J Stock Defies Gravity Slides on Earnings; Pharma M&A Heats Up in China

Johnson & Johnson (J&J) saw its shares slide nearly 3%, defying the company's decision to raise its financial guidance for 2026, as investors focused on specific operational weaknesses rather than the broader upbeat forecast. The 6.8% sales climb in its innovative medicines division, driven by blockbusters like Darzalex and Tremfya, failed to offset the negative sentiment surrounding other key segments.

Tension Between Raised Guidance and Market Skepticism

J&J's latest quarterly earnings report revealed a striking divergence between Wall Street consensus and the company's actual performance drivers. While management lifted its annual sales forecast to a range of $100.8 billion to $101.4 billion, up from previous projections, analysts at RBC Capital Markets highlighted the cracks beneath the surface:

■The company's overall oncology business missed consensus Wall Street estimates.

■Sales of the prostate cancer drug Erleada and blood cancer treatment Imbruvica fell short of expectations.

■The medical device division also delivered a disappointing performance.

■Despite these misses, analyst Shagun Singh noted that her team "remain[s] positive" on J&J's 2026 outlook and its trajectory toward "double-digit growth" by the end of the decade.

Pharma Giants Deepen Strategic Ties in China

While J&J grappled with stock volatility, AstraZeneca and Spero Therapeutics moved aggressively to bolster their pipelines through strategic deals in China, moves that could reshape the sector's global equation.

AstraZeneca struck a major deal with Shanghai-based drugmaker Dizal to secure worldwide rights to the lung cancer drug Zegfrovy. The financial structure of the deal is aggressive:

■AstraZeneca agreed to an upfront payment of $600 million.

■The total deal value could reach up to $1.5 billion.

■Zegfrovy generated approximately $85 million in sales during the 2025 fiscal year.

■Leerink Partners analyst Andrew Berens suggests the drug will add "modest revenues" to AstraZeneca's $80 billion sales target but offers significant "synergies" with existing lung cancer portfolios.

Meanwhile, Spero Therapeutics pivoted away from antibiotic development, announcing a licensing agreement with Innovent Biologics for the experimental immune disease drug IBI355. Under this partnership, Innovent stands to receive as much as $1.1 billion, including an undisclosed upfront sum, marking a strategic shift for Spero following the market entry of its drug Utebzi.

Markets are interpreting these mixed signals as a classic "sell the news" reaction within large-cap healthcare. J&J's decline despite raised guidance underscores that investors are laser-focused on segment-specific margin pressures and competitive dynamics rather than just top-line beats. Simultaneously, the aggressive licensing deals in China highlight that geographic diversification remains a critical premium driver in biotech valuations.